Cited by 101Regulation of Appetite and ObesityPharmacology and Obesity TreatmentDiabetes Treatment and Management

A Role for GLP-1 in Treating Hyperphagia and Obesity

Open access
Grill, Harvey J·2020·Endocrinology

Abstract

Obesity is a chronic recurring disease whose prevalence has almost tripled over the past 40 years. In individuals with obesity, there is significant increased risk of morbidity and mortality, along with decreased quality of life. Increased obesity prevalence results, at least partly, from the increased global food supply that provides ubiquitous access to tasty, energy-dense foods. These hedonic foods and the nonfood cues that through association become reward predictive cues activate brain appetitive control circuits that drive hyperphagia and weight gain by enhancing food-seeking, motivation, and reward. Behavioral therapy (diet and lifestyle modifications) is the recommended initial treatment for obesity, yet it often fails to achieve meaningful weight loss. Furthermore, those who lose weight regain it over time through biological regulation. The need to effectively treat the pathophysiology of obesity thus centers on biologically based approaches such as bariatric surgery and more recently developed drug therapies. This review highlights neurobiological aspects relevant to obesity causation and treatment by emphasizing the common aspects of the feeding-inhibitory effects of multiple signals. We focus on glucagon like peptide-1 receptor (GLP-1R) signaling as a promising obesity treatment target by discussing the activation of intestinal- and brain-derived GLP-1 and GLP-1R expressing central nervous system circuits resulting from normal eating, bariatric surgery, and GLP-1R agonist drug therapy. Given the increased availability of energy-dense foods and frequent encounters with cues that drive hyperphagia, this review also describes how bariatric surgery and GLP-1R agonist therapies influence food reward and the motivational drive to overeat.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endocr/bqaa093

Cites

145 of 145 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Appetitive brain areas such as the striatum, insula, and orbitofrontal cortex that are commonly activated by viewing rewarding and energy-dense food pictures are significantly reduced by GLP-1 RA.

    “Appetitive brain areas such as the striatum, insula, and orbitofrontal cortex that are commonly activated by viewing rewarding and energy-dense food pictures (13) are also significantly reduced by GLP-1 RA (14).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 2

  1. Ogden CL, Carroll MD. Prevalence of overweight, obesity, and extreme obesity among adults: United States, Trends 1960-1962 Through 2007-2008, in Division of Health and Nutrition Examination Surveys; CDCs National Center for Health Statistics; 2010:1-6.
  2. Grill A Role for GLP-1 in Treating Hyperphagia and Obesity Endocrinology, July 2020, 161(7):1-14 134.

Cited by

Sorted by citations

Authors
Grill, H. J.
Affiliations
University of Pennsylvania (US)
Corresponding author
Grill, Harvey J
Venue
Endocrinology
Published
2020-06-09
Volume
161
Issue
8
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W3033972450
Cited by
101
References
145
Citations by year
2026: 7 · 2025: 12 · 2024: 22 · 2023: 18 · 2022: 23 · 2021: 16 · 2020: 2
FWCI
1.99
Type
journal article
Language
en
Open access
Locations
  • Endocrinology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
glucagon-like peptide-1, GLP-1 receptor, obesity, hyperphagia, food reward, appetite regulation, bariatric surgery, GLP-1 receptor agonists, energy-dense foods, food cues, weight regain
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Animals, Behavior Therapy, Eating, Humans, Hyperphagia, Obesity, Weight Loss, Receptors, Glucagon, Bariatric Surgery, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review